Cargando…
Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607.
| Formato: | Online Artículo Texto |
|---|---|
| Lenguaje: | English |
| Publicado: |
The American Society of Hematology
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679801/ https://www.ncbi.nlm.nih.gov/pubmed/37966846 http://dx.doi.org/10.1182/bloodadvances.2023011828 |
| _version_ | 1785150639142076416 |
|---|---|
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10679801 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | The American Society of Hematology |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-106798012023-11-14 Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607. Blood Adv Erratum The American Society of Hematology 2023-11-14 /pmc/articles/PMC10679801/ /pubmed/37966846 http://dx.doi.org/10.1182/bloodadvances.2023011828 Text en © 2023 by The American Society of Hematology. Licensed under Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0), permitting only noncommercial, nonderivative use with attribution. All other rights reserved. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
| spellingShingle | Erratum Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607. |
| title | Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607. |
| title_full | Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607. |
| title_fullStr | Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607. |
| title_full_unstemmed | Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607. |
| title_short | Schuelke MR, Bassiri H, Behrens EM, et al. Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. Blood Adv. 2023;7(18):5603–5607. |
| title_sort | schuelke mr, bassiri h, behrens em, et al. emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients. blood adv. 2023;7(18):5603–5607. |
| topic | Erratum |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10679801/ https://www.ncbi.nlm.nih.gov/pubmed/37966846 http://dx.doi.org/10.1182/bloodadvances.2023011828 |